NCT06552520

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis in Subjects

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	TQH2722 injection	Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
DRUG	Placebo of TQH2722 injection	Placebo without drug substance

Timeline

• Start date: 2024-09-01
• Primary completion: 2025-10-01
• Completion: 2026-06-01
• First posted: 2024-08-14
• Last updated: 2024-08-14

Locations

73 sites across 1 country: China